Patent Term Extension Application for BLUJEPA (gepotidacin mesylate), Patent No. 8,389,524
🏛 Food and Drug Administration (FDA)FDA-2025-E-2426
Documents
1
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
NoticeFeb 13, 2026
Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPAOpen · 11 days left